Enteral Feeding Formulas Market

Enteral Feeding Formulas Market by Product (Polymeric, Elemental, Disease-specific), Stage (Adults, Pediatrics), Application (Oncology, Gastroenterology, Neurology, Hypermetabolism), End User (Hospitals, LTCF, Home care) - Global Forecast to 2027

Report Code: PH 4148 Aug, 2022, by marketsandmarkets.com

[233 Pages Report] The global enteral feeding formulas market is projected to reach USD 8.2 billion by 2027 from USD 5.2 billion in 2022, growing at a CAGR of 9.5% during the forecast period. Enteral feeding uses the gastrointestinal route, wherein the formula is fed either through a tube or orally. Tube feeding is the most prevalent term associated with enteral nutrition/feeding. Food and nutrition provided through a tube serve as an alternative to a traditional diet or solid food intake. Enteral feeding is largely doctor-prescribed, performed with the help of medical professionals, particularly for chronically ill patients. Different enteral formulas have been commercialized to administer nutrients through enteral formulas. Factors such as rising healthcare expenditue; a surge in the number of preterm births worldwide; growing aging population in need for enteral feeding; rising prevalence of chronic diseases such as diabetes, cancer, gastrointestinal diseases, and neurological disorders; growing awareness of enteral nutrition benifits; and rapid improvements in healthcare facilities in emerging countries are expected to further drive the market during the forecast period. Moreover, the shift from parenteral nutrition to enteral nutrition due to cost effectiveness and nutritional benifits and growing adoption for enteral feeding formulas in long term care facilities are also expected to drive the market in the coming years. However, patient safety risks; insufficient or lack of reimbursements in some developing and underdeveloped countries and a dearth of trained physicians across the globe pose significant challenges for the growth of this market.

Enteral Feeding Formulas Market

To know about the assumptions considered for the study, Request for Free Sample Report

Enteral Feeding Formula Market Dynamics

Driver: Benefits and cost-effectiveness of enteral over parenteral nutrition

Enteral feeding delivers artificial nutrients or medication through the gastrointestinal tract (including the esophagus, stomach, and small & large intestine). Parenteral feeding uses central or peripheral veins to deliver nutrients or medication intravenously into the bloodstream with a catheter. Enteral nutrition is associated with fewer complications than parenteral nutrition—a major factor driving market growth. The American Society for Parenteral and Enteral Nutrition (ASPEN) guidelines highlighted enteral nutrition as the preferred feeding route over parenteral nutrition in critically ill patients who require nutrition support therapy. Also, the cost of enteral nutrition is lower as compared to parenteral nutrition. The cost of enteral nutrition per day per person is 40% that of parenteral nutrition. Such cost benefits and affordability of enteral nutrition have impacted a significant increase in the enteral feeding formula market.

Restraint: Lack of patient Awareness

A recent study on patients with dementia observed that using feeding tubes (FTs) in patients with advanced dementia does not yield positive health outcomes and can have a negative effect. However, during the study, it was observed that there are significant gaps in knowledge among the doctors about the indications for FTs, with only 17.9% answering that there is no indication for the use of FTs in these patients with dementia. The results of this study demonstrate large gaps in knowledge among doctors on enteral feeding for patients with advanced dementia. It was also observed that despite the availability of numerous verified clinical practice guidelines focusing on enteral feeding of critically ill patients, a wide gap remains between the guideline recommendations and actual nutrition performances. Underfeeding is also a global problem. There is a current need for hospital departments to strengthen standardization and systematic EN training, provide ICU full-time nutritionists, and distribute medical resources and personnel rationally to provide minimum restraints for the market growth.

Opportunity: Emergence of new products and innovation

In the last 25 years, the number and variety of enteral formulas available for use have increased dramatically. There are over 1,000 enteral formulas now available and companies are launching new products to cater to a wider range of clients. One such example is Abbott, which in 2019 launched PediaSure Harvest product and Ensure Harvest, a new blend of real-food ingredients from sources such as mango, spinach, carrot, pumpkin and banana, to fulfil the demand for nourishing food blend formulas for tube fed patients.

Furthermore, a recent study indicated the need for high-protein enteral nutrition formulas to cater to the energy demands of the critically ill, which indicates an opportunity in this market. Further innovation is also a possibility given the expanding knowledge of disease physiopathology, composition, and functionality of food ingredients. These opportunities present strong growth potential for companies.

Challenge: Insufficient reimbursements for enteral nutrition

Enteral nutrition therapy is reimbursed in developed countries such as US, Canada, Germany, France, the UK, and Japan. However, reimbursements for enteral feeding in developing countries across the Asia Pacific, Latin America, and the Middle East are insufficient. This poses a significant challenge to the widespread adoption of enteral feeding in developing countries. Furthermore, decreasing federal funding and subsequent reimbursement cuts for home healthcare services over the next five years are expected to add to the challenges faced by players in the enteral feeding formulas market.

By Stage, Pediatrics segment registered the highest CAGR, Rise in chronic diseases for pediatrics driving market growth for pediatric patients

Based on stage, the enteral feeding formulas market is segmented into adult patients (18 years and over) and pediatric & infant patients (neonates under one month, infants between one month and two years of age, children of 2–12 years, and adolescents of 12–16 years). In 2021, the pediatrics stage accounted for higher CAGR. This can be attributed to because of the growing preterm birth rate and chronic condition in pediatrics.

By Product, Disease specific segment registered the highest CAGR,  Increased incidence of diabetes patients inducing market growth

Based on product, the global enteral feeding formulas market is segmented into standard (polymeric), peptide-based (elemental/semi-elemental), disease-specific, and other formulas. The disease specific segment registered the fastest CAGR because of Disease-specific formulas are formulated to meet the nutritional requirements of specific patient populations and increased incidence of diabetic pateints is inducting market growth for diabetic disease specific formulas.

By Application, Gastrointestinal diseases segment registered the highest CAGR,  Increasing incidenceof gastrointestinal diseases to drive the adoption of enteral feeding formulas

Based on applications, the enteral feeding formulas market is segmented into oncology, gastrointestinal diseases, diabetes, neurological disorders, and other applications. The other applications segment includes psychiatric disorders and diseases of the heart, kidney, lung, and liver and hypermetabolism. The gastrointestinal diseased application segment registered the highest CAGR. The reaseason can be attributed to the rising incidence of gastrointestinal diseases and disorders.

North America is expected to account for the largest share of the enteral feeding formula market in 2021

Enteral Feeding Formulas Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America, comprising the US and Canada, held the largest share of the enteral feeding formulas market in 2021. The enteral feeding formulas market is well-established across North America. Growth in this market is backed by the increasing prevalence of chronic diseases in North America, the presence of many well-equipped hospitals, and the gradual shift from parenteral to enteral nutrition.

Key Market Players

Prominent players in this market include Abbott (US), Nestlι S.A. (Switzerland), Danone S.A. (France), Fresenius Kabi (Germany), B. Braun Melsungen AG (Germany), Otsuka Holding Co. Ltd. (Japan), Nutritional Medicinals, LLC (US), Kate Farms (US), Medtrition Inc. (US), Victus, Inc. (US), Global Health Products, Inc. (US), Meiji Holdings Co., Ltd. (Japan), Reckitt Benckiser Group PLC. (UK), Hormel Foods Corporation (US), DermaRite Industries, LLC. (US), Medline Industries, LP. (US), Real Food Blends (US), and Ajinomoto Cambrooke, Inc. (US).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2020-2027

Base year considered

2021

Forecast period

2022–2027

Forecast units

Value (USD)

Segments covered

By Product , stage, application, and end user

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa

Companies covered

Abbott (US), Nestlι S.A. (Switzerland), Danone S.A. (France), Fresenius Kabi (Germany), B. Braun Melsungen AG (Germany), Otsuka Holding Co. Ltd. (Japan), Nutritional Medicinals, LLC (US), Kate Farms (US), Medtrition Inc. (US), Victus, Inc. (US), Global Health Products, Inc. (US), Meiji Holdings Co., Ltd. (Japan), Reckitt Benckiser Group PLC. (UK), Hormel Foods Corporation (US), DermaRite Industries, LLC. (US), Medline Industries, LP. (US), Real Food Blends (US), and Ajinomoto Cambrooke, Inc. (US)

The study categorizes the enteral feeding formula market based on product , stage, application, end user and regional & global level.

Global enteral feeding formula market, by Product

  • Standard Formula
  • Disease specific
  • Diabetic Formula
  • Renal Formula
  • Hepatic Formula
  • Pulmonary Formula
  • Other Disease Specific Formula
  • Peptide based formula
  • Other Formula

Global enteral feeding formula market, by Stage

  • Adults
  • Pediatric

Global enteral feeding formula market, by End User 

  • Hospitals
  • Long Term Care facilities
  • Nursing Homes
  • Assisted Living Facilities
  • Home Care Agencies & Hospices

Global enteral Feeding Formula Market, by Application

  • Oncology
  • Gastrointestinal Diseases
  • Neurological Disorders
  • Diabetes
  • Other Applications

Global enteral feeding formula market, by Region

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of APAC
  • Latin America
  • Middle East & Africa

Recent Developments

  • In February 2022, Nestlι (Switzerland)  agreed to purchase a majority stake in Orgain, a leader in plant-based nutrition. This acquisition would complement Nestlι Health Science’s existing portfolio of nutrition products.
  • In September 2021, Abbott (US) launched plant-based proteins and organic food ingredient enteral formulas for tube feeding.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 33)
    1.1 OBJECTIVES
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 STUDY SCOPE
          FIGURE 1 ENTERAL FEEDING FORMULAS MARKET
    1.4 YEARS CONSIDERED
    1.5 CURRENCY CONSIDERED
    1.6 LIMITATIONS
    1.7 STAKEHOLDERS
    1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 37)
    2.1 RESEARCH DATA
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 3 ENTERAL FEEDING FORMULAS MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION
          FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF ENTERAL FEEDING FORMULAS
          FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021
          FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021
    2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
          FIGURE 7 ENTERAL FEEDING FORMULAS MARKET: CAGR PROJECTIONS, 2022–2027
          FIGURE 8 ENTERAL FEEDING FORMULAS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.5 INSIGHTS FROM PRIMARIES
          FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
    2.6 RESEARCH ASSUMPTIONS
    2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 49)
    FIGURE 12 ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    FIGURE 13 ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2022 VS. 2027 (USD MILLION)
    FIGURE 14 ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 15 ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 16 GEOGRAPHIC ANALYSIS: ENTERAL FEEDING FORMULAS MARKET

4 PREMIUM INSIGHTS (Page No. - 53)
    4.1 ENTERAL FEEDING FORMULAS MARKET OVERVIEW
          FIGURE 17 INCREASING PREVALENCE OF CHRONIC DISEASES AND SHIFT FROM PARENTERAL NUTRITION TO ENTERAL NUTRITION TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET, BY TYPE (2022)
          FIGURE 18 STANDARD FORMULAS TO DOMINATE APAC ENTERAL FEEDING FORMULAS MARKET IN 2022
    4.3 ENTERAL FEEDING FORMULAS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
          FIGURE 19 MARKET IN CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
    4.4 ENTERAL FEEDING FORMULAS MARKET, BY REGION, 2020–2027
          FIGURE 20 NORTH AMERICA WILL CONTINUE TO DOMINATE ENTERAL FEEDING FORMULAS MARKET TILL 2027

5 MARKET OVERVIEW (Page No. - 57)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
          FIGURE 21 ENTERAL FEEDING FORMULAS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Benefits and cost-effectiveness of enteral over parenteral nutrition
                    5.2.1.2 Rising preterm births fueling demand for enteral feeding formulas
                                FIGURE 22 US: TOTAL NUMBER OF PRETERM BIRTHS, 2010–2020
                    5.2.1.3 Growing demand for enteral feeding in home care
                    5.2.1.4 Rapid growth in geriatric population and disease prevalence
                                FIGURE 23 ESTIMATED DIABETIC POPULATION, BY REGION, 2019 VS. 2030 VS. 2040
                                FIGURE 24 GLOBAL CANCER INCIDENCE, 2015–2040
                                FIGURE 25 US: NUMBER OF PEOPLE WITH CHRONIC CONDITIONS, 1995–2030 (MILLION INDIVIDUALS)
                                TABLE 1 DRIVERS: IMPACT ANALYSIS
           5.2.2 RESTRAINTS
                    5.2.2.1 Complications associated with enteral feeding
                                TABLE 2 COMPLICATIONS ASSOCIATED WITH ENTERAL FEEDING
                    5.2.2.2 Lack of patient awareness
                                TABLE 3 RESTRAINTS: IMPACT ANALYSIS
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emergence of new products and innovation
                    5.2.3.2 High growth opportunities in emerging countries
                                TABLE 4 OPPORTUNITIES: IMPACT ANALYSIS
           5.2.4 CHALLENGES
                    5.2.4.1 Insufficient reimbursements for enteral nutrition
                    5.2.4.2 Dearth of skilled professionals
                                TABLE 5 CHALLENGES: IMPACT ANALYSIS
    5.3 PORTER’S FIVE FORCES ANALYSIS
          TABLE 6 PORTER’S FIVE FORCES ANALYSIS
           5.3.1 THREAT FROM NEW ENTRANTS
           5.3.2 THREAT FROM SUBSTITUTES
           5.3.3 BARGAINING POWER OF SUPPLIERS
           5.3.4 BARGAINING POWER OF BUYERS
           5.3.5 COMPETITIVE RIVALRY
    5.4 REGULATORY SCENARIO
           5.4.1 REGULATORY ANALYSIS
    5.5 VALUE CHAIN ANALYSIS
          FIGURE 26 ENTERAL FEEDING FORMULAS MARKET: VALUE CHAIN ANALYSIS
    5.6 SUPPLY CHAIN ANALYSIS
          FIGURE 27 ENTERAL FEEDING FORMULAS MARKET: SUPPLY CHAIN ANALYSIS
    5.7 ECOSYSTEM MARKET MAP
          FIGURE 28 ENTERAL FEEDING FORMULAS MARKET: ECOSYSTEM MARKET MAP
    5.8 PRICING ANALYSIS
          TABLE 7 AVERAGE PRICE OF ENTERAL FEEDING FORMULAS, IN USD (2021)
          TABLE 8 AVERAGE SELLING PRICES OF ENTERAL FEEDING FORMULAS, 2017–2021 (USD)
    5.9 PATENT ANALYSIS
          FIGURE 29 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR ENTERAL FEEDING FORMULA PATENTS (JANUARY 2011–OCTOBER 2021)
          TABLE 9 INDICATIVE LIST OF PATENTS IN ENTERAL FEEDING FORMULAS MARKET
    5.10 KEY CONFERENCES AND EVENTS IN 2022–2023
           TABLE 10 ENTERAL FEEDING FORMULAS MARKET: LIST OF CONFERENCES AND EVENTS
    5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
           FIGURE 30 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR ENTERAL FEEDING PRODUCTS
    5.12 KEY BUYING CRITERIA FOR END USERS
           FIGURE 31 ENTERAL FEEDING FORMULAS MARKET: BUYING CRITERIA OF END USERS

6 ENTERAL FEEDING FORMULAS MARKET, BY STAGE (Page No. - 78)
    6.1 INTRODUCTION
          TABLE 11 ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
    6.2 ADULTS
           6.2.1 INCREASED PREVALENCE OF CHRONIC DISEASES AND NEUROLOGICAL DISORDERS IN ADULT PATIENTS TO INCREASE MARKET SHARE
                    TABLE 12 ENTERAL FEEDING FORMULAS MARKET FOR ADULTS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 13 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR ADULTS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 14 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR ADULTS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 15 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR ADULTS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 PEDIATRICS
           6.3.1 GROWING DISEASE PREVALENCE IN PEDIATRIC PATIENTS DRIVING MARKET GROWTH
                    TABLE 16 ENTERAL FEEDING FORMULAS MARKET FOR PEDIATRICS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 17 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR PEDIATRICS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 18 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR PEDIATRICS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 19 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR PEDIATRICS, BY COUNTRY, 2020–2027 (USD MILLION)

7 ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT (Page No. - 85)
    7.1 INTRODUCTION
          TABLE 20 ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
    7.2 STANDARD FORMULAS
           7.2.1 EASE OF ACCESSIBILITY AND COST-EFFECTIVENESS WILL INCREASE MARKET GROWTH
                    TABLE 21 STANDARD ENTERAL FEEDING FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 22 NORTH AMERICA: STANDARD ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 23 EUROPE: STANDARD ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 24 ASIA PACIFIC: STANDARD ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 DISEASE-SPECIFIC FORMULAS
          TABLE 25 DISEASE-SPECIFIC ENTERAL FEEDING FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 26 DISEASE-SPECIFIC ENTERAL FEEDING FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
          TABLE 27 NORTH AMERICA: DISEASE-SPECIFIC ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 28 EUROPE: DISEASE-SPECIFIC ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 29 ASIA PACIFIC: DISEASE-SPECIFIC ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           7.3.1 DIABETIC FORMULAS
                    7.3.1.1 Increased incidence of diabetes patients driving market growth
                                TABLE 30 DIABETIC FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 31 NORTH AMERICA: DIABETIC FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 32 EUROPE: DIABETIC FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 33 ASIA PACIFIC: DIABETIC FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           7.3.2 RENAL FORMULAS
                    7.3.2.1 Rise in patient population for chronic kidney disease to contribute to market growth
                                TABLE 34 RENAL FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 35 NORTH AMERICA: RENAL FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 36 EUROPE: RENAL FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 37 ASIA PACIFIC: RENAL FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           7.3.3 HEPATIC FORMULAS
                    7.3.3.1 Rise in obesity and alcohol consumption drive demand for hepatic formulas
                                TABLE 38 HEPATIC FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 39 NORTH AMERICA: HEPATIC FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 40 EUROPE: HEPATIC FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 41 ASIA PACIFIC: HEPATIC FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           7.3.4 PULMONARY FORMULAS
                    7.3.4.1 Rising disease prevalence to drive demand growth
                                TABLE 42 PULMONARY FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 43 NORTH AMERICA: PULMONARY FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 44 EUROPE: PULMONARY FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 45 ASIA PACIFIC: PULMONARY FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           7.3.5 OTHER DISEASE-SPECIFIC FORMULAS
                    TABLE 46 OTHER DISEASE-SPECIFIC FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 47 NORTH AMERICA: OTHER DISEASE-SPECIFIC FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 48 EUROPE: OTHER DISEASE-SPECIFIC FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 49 ASIA PACIFIC: OTHER DISEASE-SPECIFIC FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    7.4 PEPTIDE-BASED FORMULAS
           7.4.1 BENEFITS OF PEPTIDE-BASED FORMULAS OVER OTHER SEGMENTS POSITIVELY IMPACTING MARKET GROWTH
                    TABLE 50 PEPTIDE-BASED ENTERAL FEEDING FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 51 NORTH AMERICA: PEPTIDE-BASED ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 52 EUROPE: PEPTIDE-BASED ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 53 ASIA PACIFIC: PEPTIDE-BASED ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    7.5 OTHER FORMULAS
          TABLE 54 OTHER ENTERAL FEEDING FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
          TABLE 55 NORTH AMERICA: OTHER ENTERAL FEEDING FORMULAS MARKET, 2020–2027 (USD MILLION)
          TABLE 56 EUROPE: OTHER ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 57 ASIA PACIFIC: OTHER ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

8 ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION (Page No. - 104)
    8.1 INTRODUCTION
          TABLE 58 ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
    8.2 ONCOLOGY
           8.2.1 GROWING INCIDENCE OF CANCER TO INCREASE MARKET SHARE
                    TABLE 59 NUMBER OF NEW CANCER PATIENTS IN AMERICA
                    TABLE 60 ENTERAL FEEDING FORMULAS MARKET FOR ONCOLOGY, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 61 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 62 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 63 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 GASTROENTEROLOGY
           8.3.1 INCREASING INCIDENCE OF GASTROINTESTINAL DISEASES TO DRIVE ADOPTION OF ENTERAL FEEDING FORMULAS
                    TABLE 64 INDICATIVE LIST OF DIGESTIVE DISEASES & DISORDERS REQUIRING ENTERAL FEEDING
                    TABLE 65 ENTERAL FEEDING FORMULAS MARKET FOR GASTROENTEROLOGY, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 66 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 67 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 68 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
    8.4 NEUROLOGY
           8.4.1 HIGH BURDEN OF NEUROLOGICAL DISORDERS TO FUEL DEMAND FOR CLINICAL NUTRITION THERAPIES
                    TABLE 69 ENTERAL FEEDING FORMULAS MARKET FOR NEUROLOGY, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 70 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 71 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 72 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
    8.5 DIABETES
           8.5.1 USE OF ENTERAL FEEDING SYSTEMS IN DIABETICS HELPS PREVENT HYPERGLYCEMIA AND ASSOCIATED COMPLICATIONS
                    TABLE 73 ENTERAL FEEDING FORMULAS MARKET FOR DIABETES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 74 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR DIABETES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 75 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR DIABETES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 76 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR DIABETES, BY COUNTRY, 2020–2027 (USD MILLION)
    8.6 OTHER APPLICATIONS
          TABLE 77 ENTERAL FEEDING FORMULAS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
          TABLE 78 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 79 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 80 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)

9 ENTERAL FEEDING FORMULAS MARKET, BY END USER (Page No. - 117)
    9.1 INTRODUCTION
          TABLE 81 ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.2 HOSPITALS
           9.2.1 GROWING CHRONIC AND INFECTIOUS DISEASE PREVALENCE DRIVES MARKET GROWTH
                    TABLE 82 ENTERAL FEEDING FORMULAS MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 83 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 84 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 85 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
    9.3 LONG-TERM CARE FACILITIES
          TABLE 86 ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 87 ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2020–2027 (USD MILLION)
          TABLE 88 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 89 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 90 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2020–2027 (USD MILLION)
           9.3.1 NURSING HOMES
                    9.3.1.1 Need for nursing care in above-65 age group to drive market growth
                                TABLE 91 ENTERAL FEEDING FORMULAS MARKET FOR NURSING HOMES, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 92 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR NURSING HOMES, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 93 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR NURSING HOMES, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 94 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR NURSING HOMES, BY COUNTRY, 2020–2027 (USD MILLION)
           9.3.2 ASSISTED LIVING FACILITIES
                    9.3.2.1 Growth in chronic disease prevalence to support market growth
                                TABLE 95 ENTERAL FEEDING FORMULAS MARKET FOR ASSISTED LIVING FACILITIES, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 96 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR ASSISTED LIVING FACILITIES, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 97 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR ASSISTED LIVING FACILITIES, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 98 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR ASSISTED LIVING FACILITIES, BY COUNTRY, 2020–2027 (USD MILLION)
           9.3.3 HOME CARE AGENCIES & HOSPICES
                    9.3.3.1 Limitations associated with home care to hamper market growth
                                TABLE 99 ENTERAL FEEDING FORMULAS MARKET FOR HOME CARE AGENCIES & HOSPICES, BY REGION, 2020–2027 (USD MILLION)
                                TABLE 100 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR HOME CARE AGENCIES & HOSPICES, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 101 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR HOME CARE AGENCIES & HOSPICES, BY COUNTRY, 2020–2027 (USD MILLION)
                                TABLE 102 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR HOME CARE AGENCIES & HOSPICES, BY COUNTRY, 2020–2027 (USD MILLION)

10 ENTERAL FEEDING FORMULAS MARKET, BY REGION (Page No. - 128)
     10.1 INTRODUCTION
             TABLE 103 ENTERAL FEEDING FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
     10.2 NORTH AMERICA
             FIGURE 32 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET SNAPSHOT, 2021
             TABLE 104 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 105 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
             TABLE 106 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 107 NORTH AMERICA: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 108 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 109 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
             TABLE 110 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
             10.2.1 US
                        10.2.1.1 Advanced healthcare system and availability of reimbursement for enteral nutrition to increase market growth
                                      TABLE 111 US: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
                                      TABLE 112 US: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 113 US: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 114 US: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 115 US: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
                                      TABLE 116 US: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Increasing incidence of chronic diseases such as diabetes and cancer supports market growth
                                      TABLE 117 CANADA: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
                                      TABLE 118 CANADA: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 119 CANADA: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 120 CANADA: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 121 CANADA: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
                                      TABLE 122 CANADA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
     10.3 EUROPE
             TABLE 123 EUROPE: ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 124 EUROPE: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
             TABLE 125 EUROPE: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 126 EUROPE: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 127 EUROPE: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 128 EUROPE: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
             TABLE 129 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
             10.3.1 UK
                        10.3.1.1 High incidence of target diseases to drive UK enteral feeding formulas market
                                      TABLE 130 MACROINDICATORS FOR ENTERAL FEEDING FORMULAS MARKET IN UK
                                      TABLE 131 UK: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
                                      TABLE 132 UK: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 133 UK: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 134 UK: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 135 UK: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
                                      TABLE 136 UK: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
             10.3.2 GERMANY
                        10.3.2.1 Germany to overtake UK and dominate European market by 2027
                                      TABLE 137 MACROINDICATORS FOR ENTERAL FEEDING FORMULAS MARKET IN GERMANY
                                      TABLE 138 GERMANY: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
                                      TABLE 139 GERMANY: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 140 GERMANY: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 141 GERMANY: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 142 GERMANY: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
                                      TABLE 143 GERMANY: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Well-established healthcare system and strong government support contribute to market growth
                                      TABLE 144 MACROINDICATORS FOR ENTERAL FEEDING FORMULAS MARKET IN FRANCE
                                      TABLE 145 FRANCE: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
                                      TABLE 146 FRANCE: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 147 FRANCE: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 148 FRANCE: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 149 FRANCE: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
                                      TABLE 150 FRANCE: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 Market growth attributed to growing geriatric population and need for nursing homes in Italy
                                      TABLE 151 MACROINDICATORS FOR ENTERAL FEEDING FORMULAS MARKET IN ITALY
                                      TABLE 152 ITALY: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
                                      TABLE 153 ITALY: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 154 ITALY: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 155 ITALY: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 156 ITALY: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
                                      TABLE 157 ITALY: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Significant increase in patients opting for enteral nutrition to support market growth
                                      TABLE 158 SPAIN: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
                                      TABLE 159 SPAIN: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 160 SPAIN: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 161 SPAIN: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 162 SPAIN: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
                                      TABLE 163 SPAIN: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
             10.3.6 REST OF EUROPE
                        TABLE 164 ROE: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
                        TABLE 165 ROE: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 166 ROE: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 167 ROE: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 168 ROE: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
                        TABLE 169 ROE: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
     10.4 ASIA PACIFIC
             FIGURE 33 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET SNAPSHOT
             TABLE 170 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 171 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
             TABLE 172 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
             TABLE 173 ASIA PACIFIC: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 174 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 175 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
             TABLE 176 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
             10.4.1 JAPAN
                        10.4.1.1 Rising geriatric population to drive market growth in Japan
                                      TABLE 177 JAPAN: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
                                      TABLE 178 JAPAN: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 179 JAPAN: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 180 JAPAN: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 181 JAPAN: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
                                      TABLE 182 JAPAN: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 Growing investment in healthcare infrastructure development to drive adoption of enteral feeding formulas
                                      TABLE 183 CHINA: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
                                      TABLE 184 CHINA: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 185 CHINA: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 186 CHINA: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 187 CHINA: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
                                      TABLE 188 CHINA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Increasing incidence of preterm births and cancer cases to drive market growth in India
                                      TABLE 189 INDIA: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
                                      TABLE 190 INDIA: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 191 INDIA: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 192 INDIA: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 193 INDIA: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
                                      TABLE 194 INDIA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
             10.4.4 REST OF ASIA PACIFIC
                        TABLE 195 ROAPAC: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
                        TABLE 196 ROAPAC: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 197 ROAPAC: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 198 ROAPAC: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 199 ROAPAC: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
                        TABLE 200 ROAPAC: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
     10.5 LATIN AMERICA
             10.5.1 ECONOMIC DEVELOPMENT, INCREASING HEALTHCARE ACCESS, AND GROWING DISEASE PREVALENCE TO DRIVE MARKET GROWTH
                        TABLE 201 LATIN AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
                        TABLE 202 LATIN AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 203 LATIN AMERICA: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 204 LATIN AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 205 LATIN AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
                        TABLE 206 LATIN AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA
             10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND HEALTH INSURANCE PENETRATION TO SUPPORT MARKET GROWTH
                        TABLE 207 MIDDLE EAST AND AFRICA: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
                        TABLE 208 MIDDLE EAST AND AFRICA: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 209 MIDDLE EAST AND AFRICA: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 210 MIDDLE EAST AND AFRICA: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 211 MIDDLE EAST AND AFRICA: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
                        TABLE 212 MIDDLE EAST AND AFRICA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 181)
     11.1 OVERVIEW
     11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
             FIGURE 34 KEY PLAYER STRATEGIES IN ENTERAL FEEDING FORMULAS MARKET, 2019–2022
     11.3 MARKET SHARE ANALYSIS
             FIGURE 35 ENTERAL FEEDING FORMULAS MARKET: MARKET SHARE ANALYSIS, 2021 (TOP FIVE PLAYERS)
             TABLE 213 ENTERAL FEEDING FORMULAS MARKET: DEGREE OF COMPETITION
     11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
             FIGURE 36 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN ENTERAL FEEDING FORMULAS MARKET
     11.5 COMPANY EVALUATION QUADRANT
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 37 ENTERAL FEEDING FORMULAS MARKET: COMPANY EVALUATION QUADRANT, 2021
     11.6 COMPETITIVE BENCHMARKING
             11.6.1 COMPANY FOOTPRINT ANALYSIS
                         FIGURE 38 COMPANY FOOTPRINT ANALYSIS
             11.6.2 COMPANY PRODUCT FOOTPRINT
                         TABLE 214 PRODUCT PORTFOLIO ANALYSIS
             11.6.3 COMPANY REGIONAL FOOTPRINT
                         TABLE 215 REGIONAL REVENUE MIX
                        11.6.3.1 COMPETITIVE BENCHMARKING
                                      TABLE 216 ENTERAL FEEDING FORMULAS MARKET: DETAILED LIST OF KEY START-UPS/SMES
                                      TABLE 217 ENTERAL FEEDING FORMULAS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES)
     11.7 COMPETITIVE SCENARIO AND TRENDS
             TABLE 218 PRODUCT LAUNCHES & APPROVALS, JANUARY 2019–JULY 2022
             TABLE 219 DEALS, JANUARY 2019–JULY 2022
             TABLE 220 OTHER DEVELOPMENTS, JANUARY 2019–JULY 2022

12 COMPANY PROFILES (Page No. - 193)
     12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             12.1.1 ABBOTT
                        TABLE 221 ABBOTT: BUSINESS OVERVIEW
                        FIGURE 39 ABBOTT: COMPANY SNAPSHOT (2021)
             12.1.2 NESTLΙ
                        TABLE 222 NESTLΙ: BUSINESS OVERVIEW
                        FIGURE 40 NESTLΙ: COMPANY SNAPSHOT (2021)
             12.1.3 DANONE S.A.
                        TABLE 223 DANONE: BUSINESS OVERVIEW
                        FIGURE 41 DANONE: COMPANY SNAPSHOT (2021)
             12.1.4 FRESENIUS KABI
                        TABLE 224 FRESENIUS KABI: BUSINESS OVERVIEW
                        FIGURE 42 FRESENIUS KABI: COMPANY SNAPSHOT (2021)
             12.1.5 B. BRAUN MELSUNGEN AG
                        TABLE 225 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
                        FIGURE 43 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2021)
             12.1.6 OTSUKA HOLDINGS CO., LTD.
                        TABLE 226 OTSUKA HOLDINGS CO., LTD.: BUSINESS OVERVIEW
                        FIGURE 44 OTSUKA HOLDINGS CO., LTD.: COMPANY SNAPSHOT (2021)
             12.1.7 NUTRITIONAL MEDICINALS, LLC
                        TABLE 227 NUTRITIONAL MEDICINALS, LLC: BUSINESS OVERVIEW
             12.1.8 KATE FARMS
                        TABLE 228 KATE FARMS: BUSINESS OVERVIEW
             12.1.9 MEDTRITION INC.
                        TABLE 229 MEDTRITION INC.: BUSINESS OVERVIEW
             12.1.10 VICTUS, INC.
                        TABLE 230 VICTUS, INC.: BUSINESS OVERVIEW
             12.1.11 GLOBAL HEALTH PRODUCTS, INC.
                        TABLE 231 GLOBAL HEALTH PRODUCTS, INC.: BUSINESS OVERVIEW
             12.1.12 MEIJI HOLDINGS
                        TABLE 232 MEIJI HOLDINGS CO., LTD.: BUSINESS OVERVIEW
                        FIGURE 45 MEIJI HOLDINGS CO., LTD.: COMPANY SNAPSHOT (2021)
             12.1.13 RECKITT BENCKISER GROUP
                        TABLE 233 RECKITT BENCKISER GROUP: BUSINESS OVERVIEW
FIGURE 46 RECKITT BENCKISER GROUP: COMPANY SNAPSHOT (2021)
     12.2 OTHER COMPANIES
             12.2.1 HORMEL FOODS CORPORATION
             12.2.2 DERMARITE INDUSTRIES
             12.2.3 MEDLINE INDUSTRIES, LP
             12.2.4 REAL FOOD BLENDS
             12.2.5 AJINOMOTO CAMBROOKE, INC.

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 226)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATION OPTIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources; directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the enteral feeding formula market. It was also used to obtain important information about the key players, market classification and segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side and demand side are detailed below.

A breakdown of the primary respondents is provided below:

Enteral Feeding Formulas Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the enteral feeding formula market was arrived at after data triangulation from three different approaches, as mentioned below. After each approach, the weighted average of all approaches was taken based on the level of assumptions used in each approach.

Data Triangulation

After arriving at the market size, the total market was divided into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics for all segments and sub-segments, data triangulation and market breakdown procedures were employed, wherever applicable. The following figure shows the market validation, source structure, and data triangulation methodology implemented in this report’s market engineering process.

Objectives of the Study

  • To validate the segmentation defined through the assessment of the product portfolios of the leading players in the market
  • To understand key industry trends and issues defining the growth objectives of market players
  • To gather both demand- and supply-side validation of the key factors affecting market growth, including market drivers, restraints, opportunities, and challenges
  • To validate assumptions for the market sizing and forecasting model used for this market study
  • To understand the market positions of the leading players in the enteral feeding formula market and their shares/rankings
  • To understand the ongoing pricing trends in the market and future expectations

Available customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Geographic Analysis

  • Further breakdown of the RoE enteral feeding formula market into Sweden, Russia, Austria, Finland, and others
  • Further breakdown of the Southeast Asian enteral feeding formula market into Singapore, Vietnam, and others
  • Further breakdown of the RoLATAM enteral feeding formula market into Argentina, Colombia, Chile, and others
  • Further breakdown of the Benelux enteral feeding formula market into Belgium, the Netherlands, and Luxembourg

Competitive Landscape Assessment

  • Market share analysis for the APAC region, which provides market shares of the top 3–5 key players in the enteral feeding formula market 
  • Competitive leadership mapping for established players in the US
Enteral Feeding Formulas Market Size,  Share & Growth Report
Report Code
PH 4148
Published ON
Aug, 2022
Choose License Type
BUY NOW
GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

SEND ME A FREE SAMPLE
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status